Prenetics Group Limited (PRE): Price and Financial Metrics
PRE Price/Volume Stats
|Current price||$4.35||52-week high||$46.05|
|Prev. close||$4.20||52-week low||$3.84|
|Day high||$4.39||Avg. volume||23,303|
|50-day MA||$5.78||Dividend yield||N/A|
|200-day MA||$10.52||Market Cap||39.75M|
PRE Stock Price Chart Interactive Chart >
Prenetics Group Limited (PRE) Company Bio
Prenetics Group Limited operates as a diagnostics and genetic testing company worldwide. It develops consumer genetic testing and early colorectal cancer screening products; and provides COVID-19 testing, rapid point of care and at-home diagnostic testing, and medical genetic testing products. The company's products include CircleDNA, a consumer genetic testing offering that uses whole exome sequencing; Project Screen, a COVID-19 test; and Circle HealthPod, a molecular testing product for COVID-19. It is also developing ColoClear, a non-invasive stool-based FIT-DNA test for colorectal cancer screening; Circle SnapShot, an at-home blood test with a user-friendly blood sample collection and result delivery system; Circle Medical, a test to identify causal genetic mutations for patients; and Circle One and F1x/Fem, a DNA profile and questionnaire based personalized nutrition solution. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
PRE Latest News Stream
|Loading, please wait...|
PRE Latest Social Stream
View Full PRE Social Stream
Latest PRE News From Around the Web
Below are the latest news stories about PRENETICS GLOBAL LTD that investors may wish to consider to help them evaluate PRE as an investment opportunity.
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.
With the business potentially at an important milestone, we thought we'd take a closer look at Prenetics Global...
HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split of its outstanding ordinary shares at a ratio of 1-for-15. The reverse stock split is expected to become effective on or around November 13, 2023, subject to confirmation by NASDAQ. The Company’s common stock is expected to begin trading on a post-split basis at the market open on November 14, 2023 u
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.
A World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television
In a move that had never been seen before, marrying beauty with science, the Miss Hong Kong Pageant 2023, which just aired on TVB, had set out to revolutionize the industry by partnering with CircleDNA to unveil contestants' DNA results live on television. This ground-breaking initiative marked the first time in the history of beauty pageants worldwide that such a reveal had taken place.
PRE Price Returns